Article
Clinical Q&A
We have observed an increase in the incidence of paclitaxel-related hypersensitivity reactions at our institution. Does any new information explain the etiology of these reactions? Should we change our standards for monitoring patients receiving paclitaxel infusions (e.g., begin placing patients on cardiac monitors)?
Members Only
Access to this article is restricted. Please log in to view the full article.